Current Status of Therapy of Solid Tumors: Brain Tumor Therapy

Journal of Nuclear Medicine

Michael R. Zalutsky¹ 

[1] Departments of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina Departments of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina Departments of Radiology and Biomedical Engineering, Duke University Medical Center, Durham, North Carolina

关键词: brain tumor;    glioma;    ²¹¹At;    radionuclide therapy;    ¹³¹I;   

DOI  :  

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

Treatment of malignant brain tumors with conventional approaches is largely unsuccessful because curative doses generally cannot be delivered without excessive toxicity to normal brain. Radioimmunotherapy is emerging as an attractive alternative for glioma therapy because of the potential for more selectively irradiating tumor cells while sparing normal tissues. Several institutions are engaged in phase I and phase II trials investigating the therapeutic potential of monoclonal antibodies (mAbs) labeled with the β-emitters 131I and 90Y and the α-emitter 211At in patients with recurrent and newly diagnosed brain tumors. The current status of these trials will be discussed with regard to efficacy, toxicity, and future directions.

【 授权许可】

Unknown